The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Health care utilization and economic burden of dermatologic adverse drug reactions (ADRs) in patients with NSCLC treated with an epidermal growth factor receptor inhibitor (EGFRI).
Vijayveer Bonthapally
Employment or Leadership Position - Abbott Laboratories
Stock Ownership - Abbott Laboratories
Annie Guerin
Employment or Leadership Position - Analysis Group
Eric Q. Wu
Employment or Leadership Position - Analysis Group
Genevieve Gauthier
Employment or Leadership Position - Analysis Group
Martin Cloutier
Employment or Leadership Position - Analysis Group
Kyle D. Holen
Employment or Leadership Position - Abbott Laboratories
Stock Ownership - Abbott Laboratories
Saurabh Ray
Employment or Leadership Position - Abbott Laboratories
Stock Ownership - Abbott Laboratories